PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930168
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930168
The global microarrays market size was valued at USD 6.85 billion in 2025 and is projected to grow from USD 7.25 billion in 2026 to USD 12.72 billion by 2034, exhibiting a CAGR of 7.27% during the forecast period. North America dominated the microarrays market with a market share of 43.35% in 2025, supported by strong research infrastructure and high adoption of advanced genomic technologies.
Microarrays are laboratory tools that enable the simultaneous analysis of thousands of genes or proteins from a single sample. These tools use hybridization-based techniques and consist of a solid surface, typically a glass slide, embedded with probes made of DNA, RNA, or proteins. Increasing genomic research activities, rising demand for innovative therapies, and continuous technological advancements are driving the adoption of microarray technologies globally.
Leading players such as Illumina Inc., Thermo Fisher Scientific Inc., and Agilent Technologies Inc. hold a strong position due to their broad product portfolios, consistent innovation, and global geographic presence.MARKET DYNAMICS
MARKET DRIVERS
Rising Incidence of Chronic and Infectious Diseases to Propel Market Growth
The growing global burden of chronic and infectious diseases is increasing the demand for advanced molecular profiling tools. Microarrays enable early diagnosis, biomarker discovery, disease surveillance, and personalized treatment strategies. Gene expression arrays, methylation arrays, and protein arrays offer high-throughput and cost-effective solutions for large-scale studies.
According to the National Cancer Institute, approximately 2,041,910 new cancer cases were estimated to be diagnosed in the U.S. in 2025, reinforcing the need for advanced diagnostic and research tools such as microarrays.
MARKET RESTRAINTS
Increasing Adoption of Alternative Advanced Technologies to Restrict Market Expansion
The increasing preference for next-generation sequencing (NGS) is restraining the growth of the microarrays market. NGS provides higher sensitivity, broader genomic coverage, and the ability to detect novel genetic variants. These advantages make NGS a preferred option for applications such as precision medicine and non-invasive prenatal testing (NIPT). As a result, microarrays face competitive pressure in several clinical and research applications.
MARKET OPPORTUNITIES
Growing Focus on Personalized Medicine
Personalized medicine is creating lucrative growth opportunities for the microarrays market. Microarrays support rapid patient stratification, biomarker validation, and companion diagnostics development. Their cost-effectiveness for large population studies makes them attractive for pharmaceutical companies, diagnostic laboratories, and research institutes. Integration with AI-driven analytics and expansion into protein and methylation arrays further enhances their clinical relevance.
MARKET CHALLENGES
High Cost of Instrumentation and Maintenance
Microarray systems require expensive scanners and specialized laboratory infrastructure. High initial investment, maintenance costs, and the need for skilled professionals and bioinformatics expertise limit adoption, particularly in small laboratories and emerging economies. For instance, the SpotLight Turbo Microarray Scanner costs approximately USD 73,510, creating a financial barrier for new entrants.
MICROARRAYS MARKET TRENDS
Increasing Usage of Protein and Specialized Microarrays
Protein and specialized microarrays are gaining significant traction due to their ability to analyze thousands of proteins simultaneously. These arrays support applications in cancer research, autoimmune disease studies, and drug discovery. Advancements in surface chemistry, cell-free protein expression, and data analytics are enhancing sensitivity, specificity, and reproducibility, driving future market growth.
SEGMENTATION ANALYSIS
By Offering
The products segment dominated the market with a 60.92% share in 2026, driven by strong demand from research institutions, pharmaceutical companies, and diagnostic laboratories. Continuous product launches, such as Thermo Fisher Scientific's chromosomal microarray introduced in August 2023, further support segment growth.
By Type
The DNA microarrays segment dominated the market in 2024, supported by widespread use in genotyping, gene expression analysis, and drug development. The protein microarrays segment is expected to grow at a CAGR of 12.68% during the forecast period.
By Application
The research segment held a 45.46% market share in 2026 and is expected to account for 46.1% in 2025, driven by extensive use in genomics, disease characterization, and biomarker discovery. The diagnostics segment is projected to grow at a CAGR of 8.96%.
By End User
Research and academic institutes accounted for 45.14% of the market in 2026 and are expected to hold 45.7% in 2025, supported by early adoption and government funding initiatives.
REGIONAL OUTLOOK
North America led the market with a valuation of USD 2.97 billion in 2025, with the U.S. accounting for USD 2.87 billion.
Europe reached USD 1.57 billion in 2025, growing at a CAGR of 6.53%.
Asia Pacific attained USD 1.54 billion in 2025, with China and India reaching USD 0.46 billion and USD 0.24 billion respectively in 2026.
Latin America recorded USD 0.40 billion in 2025, while Middle East & Africa (GCC) reached USD 0.15 billion.
COMPETITIVE LANDSCAPE
The market is moderately fragmented, with major players focusing on innovation, geographic expansion, and bioinformatics services. Companies such as Agilent Technologies Inc., Thermo Fisher Scientific Inc., Illumina Inc., and Merck KGaA continue to strengthen their market presence through strategic collaborations and advanced product offerings.
Conclusion
The global microarrays market demonstrates steady and sustainable growth, supported by increasing applications in genomics research, diagnostics, and drug discovery. Valued at USD 6.85 billion in 2025, the market is expected to expand to USD 7.25 billion in 2026 and further reach USD 12.72 billion by 2034, registering a CAGR of 7.27% during the forecast period. Strong demand for high-throughput molecular profiling tools, coupled with rising prevalence of chronic and infectious diseases, continues to drive market expansion.
Despite competitive pressure from advanced technologies such as next-generation sequencing, microarrays retain significant relevance due to their cost-effectiveness, reproducibility, and suitability for large-scale studies. Growth opportunities are further strengthened by the rising focus on personalized medicine, increasing use of protein and specialized microarrays, and continuous technological advancements in array design and data analytics.
Regionally, North America dominated the market in 2025, supported by robust research infrastructure, high R&D spending, and strong presence of leading market players. Europe and Asia Pacific also present notable growth potential, driven by expanding genomics research and increasing healthcare investments. Overall, supported by ongoing innovation, expanding applications, and growing adoption across research, diagnostics, and pharmaceutical sectors, the microarrays market is expected to maintain consistent growth throughout the forecast period.
Segmentation By Offering
By Type
By Application
By End User
By Region